Trade Names:Lotensin HCT- Tablets 5 mg benazepril/6.25 mg hydrochlorothiazide- Tablets 20 mg benazepril/25 mg hydrochlorothiazide- Tablets 20 mg benazepril/12.5 mg hydrochlorothiazide- Tablets 10 mg benazepril/12.5 mg hydrochlorothiazide
Competitively inhibits angiotensin I-converting enzyme, resulting in the prevention of angiotensin I conversion to angiotensin II, a potent vasoconstrictor that stimulates aldosterone secretion. This action results in a decrease in sodium and fluid retention, increase in diuresis and a decrease in BP.Hydrochlorothiazide
Increases chloride, sodium, and water excretion by interfering with transport of sodium ions across renal tubular epithelium.
Treatment of hypertension. This fixed combination drug is not intended for the initial therapy of hypertension.
Anuric patients; patients hypersensitive to benazepril or any other ACE inhibitor; hydrochlorothiazide or other sulfonamide derivative.
PO Combination therapy with once-daily doses of 5 to 20 mg benazepril and 6.25 to 25 mg of hydrochlorothiazide in the morning and evening; take this medicine with or without food.
Store tablets at controlled room temperature (less than 86°F). Keep container tightly closed. Protect from moisture and light.
May impair the absorption of hydrochlorothiazide.Insulin
In diabetic patients, requirements of insulin may be increased, decreased, or unchanged.Lithium
Plasma levels of lithium may be elevated, increasing the risk of toxicity.Potassium supplements, potassium-sparing diuretics (eg, spironolactone)
Increased risk of hyperkalemia.Tubocurarine
Effects may be increased.
Hydrochlorothiazide may decrease serum protein-bound iodine levels without signs of thyroid disturbances.
Postural dizziness; hypotension; palpitations; syncope; tachycardia; peripheral vascular disorder; orthostatic hypotension.
Dizziness; headache; fatigue; somnolence; insomnia; nervousness; vertigo; lightheadedness; weakness; restlessness.
Rash; sweating; photosensitivity; purpura; urticarial rash; Stevens-Johnson syndrome.
Tinnitus; rhinitis; sinusitis; transient blurred vision; xanthopsia.
Nausea; vomiting; diarrhea; dyspepsia; anorexia; constipation; dry mouth; paresthesia; taste perversion; pancreatitis; sialadenitis; cramping; gastric irritation.
Impotence; urinary frequency; decreased libido.
Aplastic anemia; agranulocytosis; leukopenia; thrombocytopenia.
Intrahepatic cholestatic jaundice.
Gout; hyperglycemia; glucosuria.
Cough; upper respiratory infection; respiratory distress (including pneumonitis, pulmonary edema).
Hypertonia; angioedema (including edema of lips and face); flushing; arthralgia; myalgia; asthenia; pain (including chest and abdominal); back pain; flu-like syndrome; muscle spasm; necrotizing angiitis.
When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, discontinue therapy as soon as possible.
Ensure that volume and/or salt depletion have been corrected before initiating therapy. Monitor and record BP and pulse. Should hypotension result, hold medication and notify health care provider. Monitor blood sugar in diabetic patient when drug is started or dose is changed. Report significant changes to health care provider.
Category D (second and third trimester); Category C (first trimester). ACE inhibitors (eg, benazepril) can cause injury or death to fetus if used during second or third trimester. When pregnancy is detected, discontinue as soon as possible.
Excreted in breast milk.
Safety and efficacy not established.
Use with caution.
Use with caution.
Use with extreme caution in patients with hereditary angioedema. Angioedema associated with laryngeal edema may be fatal.
Decreases in BP may occur, especially in salt- or volume-depleted patients as a result of dialysis, prolonged diuretic therapy, dietary salt restriction, diarrhea, or vomiting. Volume and salt depletion should be corrected before initiating therapy with benazepril/hydrochlorothiazide.
Has occurred with other ACE inhibitors.
Dehydration, electrolyte disturbances, hypotension.
Copyright © 2009 Wolters Kluwer Health.